Company: SUPN
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0001356576-25-000011
Chunk: 1

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-24
Form: 8-K
Item: Item 5.02
Chunk 1
---
, Quality, GMP Operations and IT, was increased from $377,400 to $392,500. Mr. Mottola was awarded a 2024 bonus of $140,001 and was granted options to purchase 20,000 shares of common stock, 4,500 RSUs and 5,000 PSUs, which will vest depending upon the level of achievement of specified performance goals. Mr. Mottola’s bonus target for 2025 is unchanged from 2024 and is 35% of his base salary.

On February 20, 2025, the Committee recommended, and the Board approved, modifications of the compensation of the Company’s executive officers other than the Chief Executive Officer, as follows:

The annual base salary of Jack A. Khattar, the Company’s President and Chief Executive Officer, was increased from $1,001,500 to $1,036,000. Mr. Khattar was awarded a 2024 bonus of $826,254 and was granted options to purchase 331,6600 shares of common stock and 198,996 PSUs, which will vest depending upon the level of achievement of specified performance goals. In addition, Mr. Khattar’s bonus target for 2025 is unchanged from 2024 and is 75% of his base salary.

These increases were the result of the Committee’s annual compensation review for executive officers. These increases in annual base salary became effective as of January 1, 2025, and are consistent with the Company’s industry peer group and were recommended to the Committee by the Human Capital Solutions practice of Aon plc, its independent compensation consulting company.

The stock option grants and RSU awards are subject to the terms and conditions of the Company’s form of Non-Statutory Time-Based Stock Option Agreement (the “ Option Agreement”) and Restricted Stock Unit Award Agreement (the “ RSU Agreement”), respectively. Pursuant to such agreements, vesting for all stock option grants and RSUs will occur annually in equal increments over a four year period. The exercise prices for the executive officer option grants are $33.52 per share and $34.59 per share, based on the closing prices of February 19, 2025 and February 20, 2025, respectively, the dates of approval of the grants by the Committee and the Board. All other terms and conditions of the Company’s compensatory arrangements with these executive officers remain unchanged.

The PSU awards are subject to the terms and conditions of the Company’s